LASCCO and Abionic grant China license for Sepsis test

Fapon Biotech and the biotech firms LASCCO SA and Abionic SA, based in Epalinges in the canton of Vaud, have agreed a strategic cooperation for PSP sepsis diagnosis in China. According to a press release, the Chinese company Fapon, which is headquartered in the city of Dongguan in Guangdong province in southern China, has been granted an exclusive license to utilize the pancreatic stone protein (PSP) biomarker for sepsis diagnosis in China. The strategic partnership will allow Fapon to carry out research, development, manufacturing and commercialization activities with regard to PSP raw materials and chemiluminescent immunoassay (CLIA)-based reagent solutions on the Chinese market, the press release explains further.

Performing PSP testing on high-risk individuals may indicate potential sepsis before the onset of clinical symptoms. Early detection enables timely intervention and treatment, resulting in a lower risk of organ dysfunction, improved survival rates and optimized allocation of medical resources, as Fapon writes in the press release.

PSP is a reliable biomarker for the prediction of sepsis and has been patented in many countries. The PSP immunoassay has been awarded the CE mark approval in addition to Australian registration with the country’s health authority. Clearance from the US Food and Drug Administration is expected in 2024, the press release explains.

The new partnership is seen as a way for the three companies to leverage their respective technological, medical and market expertise by joining forces for the rapid screening and clinical diagnosis of sepsis, in addition to establishing guidelines for the use of antibiotics. ce/gba